Introduction
Pulmonary complications occur in up to 60% of all hematopoietic stem cell transplantation (HSCT) recipients, accounting for about 30% of all deaths. These include bacterial, fungal and viral pneumonias, noninfectious complications including bronchiolitis obliterans, lung injury due to drug toxicity or radiation and alveolar hemorrhage (AH). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The etiology of AH in transplant setting is poorly understood. Infections, cardiac causes including heart failure, toxicity from pretransplant thoracic radiation, chemotherapy, early marrow engraftment, GVHD and cytokines have been postulated to have a role in the pathogenesis of AH after HSCT. [11] [12] [13] [14] [15] [16] [17] [18] The reported mortality associated with AH varies from 70 to 100%. [11] [12] [13] [14] Diffuse AH (DAH) was initially described in autologous HSCT recipients and since has been described with equal frequency in both allogeneic and autologous transplant recipients. 13, [19] [20] [21] It is seen in 1-19% of HSCT recipients who undergo bronchoscopy. 3, 4, 12, [22] [23] [24] DAH is characterized by the presence of multilobar pulmonary infiltrates and symptoms of pneumonia and hypoxia. In addition, a patient should have progressively bloodier return on bronchoalveolar lavage (BAL) from three separate subsegmental bronchi or the presence of X20% hemosiderinladen macrophages in the absence of a clear cardiac or infective etiology for hemorrhage. [11] [12] [13] [14] [15] 25 The BAL appearance and iron stain are complementary. Soon after the onset of hemorrhage, BAL may be bloody and the iron stain may be negative. After 48-72 h, the gross appearance of BAL may not remain bloody. At this time, presence of X20% hemosiderin-laden macrophages suggests AH. Smokers may have an elevated number of hemosiderinladen macrophages and as such, using X20% hemosiderinladen macrophages as the cutoff, decreases false-positive results. 11, 26 The bronchoscopic criteria used to diagnose DAH are nonspecific and may be seen in association with diffuse lung injury from a wide variety of causes including engraftment syndrome, idiopathic pneumonia syndrome, sepsis, etc. In the post-HSCT setting, DAH syndrome is a retrospective diagnosis. Prospectively in the clinical setting, patients usually present with clinical features of pneumonia and diffuse radiologic infiltrates leading to bronchoscopy. If the BAL is progressively bloody, a diagnosis of AH is made and later if no organism is isolated in BAL, it is labeled as DAH. At treatment initiation, one usually does not know whether an infectious agent is associated with the AH, as cultures are often delayed by several days. Therefore, definitive treatment decisions are based on finding AH on bronchoscopy in the appropriate clinical setting. We therefore sought to describe the incidence, clinical course and outcomes associated with the bronchoscopic diagnosis of AH in HSCT patients at our center.
Systemic high-dose steroids and platelet transfusions are typically used for the treatment of DAH. 19, [27] [28] [29] Recent reports have suggested that the administration of recombinant factor VIIa to patients with DAH results in rapid clinical improvement and better survival. 30, 31 We also studied the outcomes of patients who received factor VIIa for AH at our center.
Patients and methods
The study was started in July 2005. Because most of the events occur within the first 6 months after HSCT, after obtaining approval from the institutional review board, we retrospectively reviewed records of all adult patients who underwent bronchoscopy between January 1, 2002 and December 31, 2004 at The University of Texas MD Anderson Cancer Center. From these records, we identified all patients who underwent bronchoscopy after HSCT. For these patients, the electronic clinical notes, bronchoscopy, radiology, pathology and microbiology reports were reviewed. Data were recorded for patients who underwent bronchoscopy for respiratory compromise with diffuse radiographic infiltrates. We reviewed patients undergoing bronchoscopy because evidence of AH on bronchoscopy is an essential feature for making the diagnosis of AH. The pediatric population was excluded because bronchoscopy is not routinely performed in children by our service.
The criteria for bronchoscopy included clinical suspicion of pneumonia with hypoxia and diffuse radiographic infiltrates. In patients with a platelet count of o20 Â 10 9 /l or international normalized ratio (INR) 42, platelets or fresh-frozen plasma was transfused before BAL as per the institutional protocol. No patient underwent intubation for bronchoscopy. Bronchoscopy and BAL were performed in all patients with the above clinical findings who presented with hemoptysis. Bronchoscopy was carried out using the EVIS EXERA BF-P160 video bronchoscope (Olympus) under mild sedation using intravenous fentanyl and midazolam. Topical anesthesia was achieved with 2% methyl paraben free (MPF) lidocaine. With patients in a recumbent or semirecumbent position, the bronchoscope was wedged into an appropriate segment after airway inspection and BAL was carried out using 60-120 cc of 0.9% saline.
The patient characteristics including demography, underlying disease, pretransplant and pulmonary function tests (PFTs) were recorded. A history of tobacco or alcohol use during 1 year before presentation was considered positive. Accurate information about past tobacco or alcohol use or pack years of tobacco use was not available. We categorized and recorded disease status at HSCT based on the criteria published by Ho et al. 32 The preconditioning regimen, HLA matching, type of HSCT, neutrophil recovery, number of transplants received and history of GVHD were also extracted. The clinical presentation, interval time from HSCT to bronchoscopy, radiographic and BAL findings, thrombocytopenia (o60 Â 10 9 /l), neutropenia (absolute neutrophil count o0.5 Â 10 9 /l), or renal dysfunction (blood urea nitrogen 440 mg/dl or serum creatinine 41.5 mg/dl) at the time of bronchoscopy and the treatment given were recorded. High-dose steroid was defined as 250 mg/day or higher methylprednisolone or its equivalent.
For this report, a diagnosis of AH was made if the following criteria were fulfilled:
1. Symptoms (like dyspnea, cough, fever) and signs (like tachypnea, tachycardia) of pneumonia with respiratory compromise; 2. Evidence of widespread alveolar injury manifested by multilobar pulmonary infiltrates seen on chest radiographs; 3. No evidence of cardiogenic pulmonary edema based on clinical findings or cardiac echocardiography; 4. BAL showing progressively bloodier returns from three subsegmental bronchi or the presence of 20% or more hemosiderin-laden macrophages.
A diagnosis of DAH syndrome was made if the patients met the additional criterion of having no bacterial, viral or fungal pathogens detected in the BAL fluid.
All patients were followed for at least 6 months after bronchoscopy or until death. The last follow-up date was June 30, 2005 . Data from index bronchoscopy for patients with AH and first bronchoscopy for respiratory compromise with diffuse infiltrates in non-AH patients were used for comparison. Data from the most recent HSCT, before the studied bronchoscopy, was used for patients undergoing more than one HSCT. Outcome measures analyzed included requirement for positive pressure ventilation over the 6 months following bronchoscopy, the length of index hospitalization and survival.
Microbiologic techniques
Gram stain and bacterial culture were performed on all BAL specimens. Fungal cultures, viral cultures and viral antigen studies for cytomegalovirus, respiratory syncytial virus and influenza A antigen were carried out on all samples. All samples were sent for cytologic studies using Papanicolaou, Giemsa and methenamine silver stains. Acid-fast stain was carried out on patients with a recent history of exposure to tuberculosis, gradual onset of symptoms, positive tuberculin test and otherwise when clinically indicated.
Statistical analysis
Pearson w 2 tests, Fisher's exact tests and Wilcoxon rank sum tests were used in bivariate analyses to examine the association between AH diagnosis and demographic and clinical characteristics. We used logistic regression techniques to model the probability of AH (presence or absence) and computed odds ratios and the associated 95% confidence intervals (CI) for predictor variables. The variables analyzed included age, gender, race, prior radiation therapy to lung, number of HSCTs, status of underlying disease at HSCT, FEV1/FVC o70 before HSCT, preconditioning regimen, type of HSCT, source of stem cells, renal dysfunction, thrombocytopenia, time to neutrophil recovery and presence of organism in BAL. Because the number of patients treated with a particular preconditioning regimens was small, the preconditioning regimens were analyzed in four groups: (1) busulfan þ fludarabine; (2) melphalan þ fludarabine; (3) carmustine (BCNU) þ etoposide þ cytarabine (Ara-C) þ melphalan; and (4) others. The other regimens included busulfan þ cyclophosphamide, cyclophosphamide þ antithymocyte globulin, fractionated cyclophosphamide þ vincristine þ adriamycin þ dexamethasone (hyper-CVAD), cyclophosphamide þ fludarabine þ alemtuzmab and melphalan. Analysis based on the underlying disease before HSCT could not be performed due to the small number of patients in each disease group.
Univariate logistic regression analyses were conducted for each predictor variable. Variables that were associated with AH occurrence at Pp0.10 and had less than 10% missing values were entered simultaneously for the full model. The full model was reduced using backward elimination to remove variables one at a time to arrive at a final reduced model. We constructed survival curves using the Kaplan-Meier method and compared the curves using log-rank test.
Univariate and multivariate Cox proportional hazards regression models were used to investigate whether any clinical factors were prognostic for survival. Time from bronchoscopy to last follow-up was used for overall survival time. The factors entered into the model were patient's age, gender, race, radiation therapy to lung before HSCT, pre-HSCT PFT, preconditioning regimens used for HSCT, use of total body irradiation during preconditioning, time to neutrophil recovery after HSCT, renal dysfunction, platelet count and absolute neutrophil count at the time of bronchoscopy, presence of AH and isolation of an organism in BAL. All reported P-values are two sided at a significance level of 5%. Analyses were performed using SAS for Windows (release 9.0; SAS Institute Inc., Cary, NC, USA).
Results
This study included 223 patients who underwent bronchoscopy between January 1, 2002 and December 31, 2004 for a clinical suspicion of AH. The follow-up period ranged from less than 1 to 42 months (median ¼ 5 months). Thirtyfour of the 223 patients were on mechanical ventilation before bronchoscopy. Of these, 21 were found to have AH. The neutrophil count recovered after a median of 12 days (range: 5-31) and platelet count recovered after a median of 14 days (range: 6-29).
Eighty-seven patients (39%) met the predefined diagnostic criteria for AH. The remaining 136 patients (61%) constituted the 'No AH' group. This group of patients had clinical and radiographic features suggestive of AH, but did not have bronchoscopic evidence of hemorrhage. Hemosiderin values were available for all 223 patients. The median levels were 20% (range: 0-95%) for patients with AH and 0% (range: 0-99%) for patients with no AH. Of the 87 patients with AH, 47 were diagnosed by progressively bloody BAL and 40 by hemosiderin-laden macrophages. The demographic and transplant characteristics of both groups are given in Table 1 . All patients in the AH and 133 in the No AH group received high-dose steroids, which were discontinued in the No AH group after bronchoscopy. All patients received aggressive treatment with antimicrobials, blood product transfusion, intensive care and mechanical ventilation as necessary. Antimicrobial prophylaxis included a combination of oral trimethoprim-sulfamethoxazole and voriconazole. Intravenous vancomycin, meropenam and voriconazole were used for empiric antimicrobial coverage. Table 2 shows the underlying diseases for which HSCT was performed. Eighty-nine (40%) of the patients received more than one bronchoscopy and 15 patients (7%) underwent bronchoscopic biopsy along with BAL. No complications associated with bronchoscopic biopsy were noted. Patients with AH underwent bronchoscopy, a median of 3 days (range: 0-105), following HSCT while those with no AH underwent bronchoscopy, a median of 6 days (range: 0-187) after HSCT (P ¼ 0.008). Hemoptysis was present in 35 (16%) of patients while 65 (29%) had pleural effusion on chest X-ray.
During the follow-up period, 132 (59%) patients died. The most frequent cause of death in both groups was respiratory failure (Table 3) . Sixty-four percent of patients with AH required positive pressure ventilation within 6 months after bronchoscopy compared to 39% among patients without AH (P ¼ 0.0002). Patients with AH (median ¼ 3 months; 95% CI: 1, 5 months) had shorter overall survival than did patients without AH (median ¼ 9 months, 95% CI: 5, 25 months; P ¼ 0.007). We found no statistically significant differences in outcomes between patients with early (within 30 days of HSCT) and late onset of AH.
The outcomes were also studied based on the isolation of an organism in BAL. Twenty-five BALs in 18 patients (8%) underwent acid-fast staining. The stain was not positive in any of these patients. In 95 of the 223 patients (43%), an organism was isolated from BAL ( Table 4 ). The organisms were isolated by culture (64%), cytology (21%), culture and cytology (11%), and positive viral antigen (4%). During follow-up, 65 (68%) of the 95 patients, found to have organisms on BAL died, and 67 (52%) deaths were observed among the remaining 128 patients. Patients in whom an organism was identified had shorter overall survival (median ¼ 5 months, 95% CI: 2, 7 months) compared to that of patients in whom no organism was identified (median ¼ 8 months, 95% CI: 5 months, data not attained; P ¼ 0.02). The 6-month overall survival rate in patients with an isolated organism was 40% (95% CI: 30, 50) versus 56% (95% CI: 46, 64) in patients without an isolated organism.
Patients were stratified further into four subgroups based on AH diagnosis and microbial organism status. Of the 87 patients with evidence of AH, 34 (39%) were found to have a microbial organism on BAL. Fifty-three (61%) patients had AH without any organism on BAL and thus met the Table 5 ). In pair-wise comparisons, the only statistically significant differences in overall survival were between patients who had AH and infection compared to each of the other three groups. The hazard of death was evaluated using Cox proportional hazards analysis. In the multivariate reduced model, isolation of an organism in BAL (hazards ratio (HR) ¼ 1.99, 95% CI: 1.38, 2.87), renal dysfunction (HR ¼ 2.35, 95% CI: 1.60, 3.46) and neutropenia (HR ¼ 2.77, 95% CI: 1.91, 4.01) were statistically significant predictors of decreased overall survival (Table 6 ). Of note, AH was not an independent predictor of survival time in the reduced multivariate model.
Recombinant factor VIIa was administered to 24 (28%) of the 87 patients with AH. Along with factor VIIa, 16 patients received platelet transfusions to keep platelet count above 50 Â 10 9 /l, four received desmopressin (1-deamino-8-D-arginine vasopressin,) and three received aminocaproic acid. Among patients who received factor VIIa, overall Table 2 Indication for stem cell transplantation in the study population Table 4 Frequency of organisms isolated in bronchoalveolar lavage Outcome of alveolar hemorrhage S Gupta et al survival, requirement for positive pressure ventilation, respiratory failure as the cause of death and duration of hospital stay after bronchoscopy were similar to those of other patients. No thrombotic complications were observed with the administration of factor VIIa in any of these patients. Logistic regression was used to identify factors associated with diagnosis of AH among patients with suspected AH (Table 7 ). In the multivariate reduced model, renal dysfunction, thrombocytopenia and use of busulfan þ fludarabine or melphalan þ fludarabine for preconditioning were found to have significant associations with AH. Other demographic and clinical characteristics including age, gender, race, prior radiation therapy to lung, pre-HSCT PFT, number of HSCTs, status of underlying disease at HSCT, source of stem cells, other preconditioning regimens, time to neutrophil recovery and presence of organism in BAL were not significantly associated with AH.
Discussion
In this study, we found that AH developed in 39% of the patients for up to 15 weeks after HSCT. Patients with AH who had an organism isolated in the BAL had worse outcomes compared to patients whose BAL was sterile.
Our study has several strengths. First, it is among the largest series with a long follow-up of AH occurring after HSCT as compared to other studies. 4, 14, 20, 22, 32 Also, we have presented outcome data on patients with possible respiratory infection and have found that infection is an independent predictor of outcome. Other studies have excluded this group of patients.
14 In addition, we have used well defined criteria for the diagnosis of AH, whereas other similar studies have determined AH using less explicit criteria. 4, 20, 22 Our study is limited due to its retrospective nature and due to the possibility of referral bias. Furthermore, we cannot establish the actual incidence of AH after HSCT due to verification bias. Determining the incidence of AH would require performing bronchoscopy in all HSCT patients irrespective of their symptoms. Thus, the study can determine the incidence of AH only in patients undergoing bronchoscopy after HSCT. Also, we do not have data on patients who might have had a similar clinical presentation but did not undergo bronchoscopy. Thus, the incidence of AH is probably underestimated.
The contribution of respiratory infections in the causation of AH and clinical significance of isolating an organism in BAL has not been well characterized. In our study, a substantial proportion of the AH cases had evidence of an organism in their BAL. Despite aggressive antimicrobial prophylaxis, the mortality of patients with an organism isolated in BAL was significantly higher. In general, patients who developed infections had poorer survival and patients who had both AH and an organism in BAL fared the worst. Thus, patients who develop infections have poorer survival. But, many of the isolated organisms are colonizers of the upper respiratory tract in immunocompromized patients and their isolation does not necessarily mean infection.
Most reports have described poor survival (usually less than 20-25% 6-month survival) for patients with DAH. 11, 13, 14 Contrary to this, in our patient population with AH (including infections), the estimated survival using the Kaplan-Meier method at 30 days was 55% and at 6-months it was 38%. These outcomes are better than previous published reports. The exact reasons for the improved survival are unclear. However, the better out- Table 5 Outcomes of alveolar hemorrhage diagnosis and the presence of a MO in BAL Outcome Alveolar hemorrhage No alveolar hemorrhage P-value patients without alveolar hemorrhage (AH) and any microbial organism (MO) in BAL, (2) patients with AH but no microbial organism in BAL, (3) patients without AH but having microbial organism in BAL, (4) patients with both AH and MO in BAL.
Outcome of alveolar hemorrhage S Gupta et al comes in our patients may be related to the use of improved diagnostic and supportive medical technologies coupled with a proactive management strategy practiced at our institution. Though most (87%) of AH cases occurred within 3 weeks after transplant, patients developed AH up to 15 weeks after HSCT. Similar to some previous studies, these results suggest that AH is a common cause of pulmonary infiltrates after HSCT and its occurrence is not limited to certain periods after the transplant. 9 Thus, AH should be included in the differential diagnosis of late-onset pulmonary complications.
Factor VIIa use was not associated with improved outcomes in these patients. This must be interpreted with caution due to the possibility of selection bias whereby sicker patients might have been more likely to receive factor VIIa. But it is important to note that out of 24 patients who received factor VIIa, none developed any thrombotic complications.
Conclusions
We present a large series on stem cell transplant patients undergoing bronchoscopy for respiratory compromise with diffuse radiographic infiltrates. AH is a common cause of pulmonary infiltrates. The occurrence of AH is not limited to certain periods after HSCT and should be included in the differential diagnosis of late-onset pulmonary complications. The mortality of these patients is improving and long-term survival of patients with DAH is feasible. Isolation of a microbial organism in BAL is a strong adverse prognostic marker. Table 6 Cox proportional hazards regression analysis for overall survival among patients undergoing bronchoscopy for respiratory compromise with diffuse infiltrates after hematopoietic stem cell transplant 
